|
|
||||||||
CLINICAL STUDY |
Laiko Hospital, Medical School, University of Athens, Endocrine Section, First Department of Medicine, Athens, Greece, 1 Alexandra University Hospital, Medical School, University of Athens, Vascular Laboratory, Department of Clinical Therapeutic, Athens, Greece and 2 Laboratory of Biological Chemistry, University of Athens Medical School, Athens, Greece
(Correspondence should be addressed to E Diamanti-Kandarakis, Athens University School of Medicine, Laiko, General Hospital, 1A Zefyrou str, Athens 14578, Greece; Email: akandara{at}otenet.gr)
Objective: The aim of this study was to investigate the endothelial status in young women with polycystic ovary syndrome (PCOS), using a simple and easily reproducible hemodynamic method combined with a biological marker and to evaluate the effect of metformin treatment on these parameters.
Design: Descriptive clinical trial.
Methods: Forty young women, 20 with PCOS and 20 normal women of similar age and body mass index were studied. Metformin (1700 mg daily) was administered for 6 months to the PCOS group. The endothelium status and the metabolic and hormonal profile were studied in both groups, as well as after metformin, by flow-mediated dilatation (FMD) on the brachial artery and by measurements of plasma endothelin-1 (ET-1) levels.
Results: FMD was impaired in the PCOS group when compared with controls (3.24±0.71% vs 8.81±1.07% respectively, P < 0.0001), but this difference normalized after metformin treatment (PCOSpost-metformin vs controls: 8.17±1.26 vs 8.81±1.07%, P = 0.70) since the values significantly improved after metformin treatment (PCOSpre-metformin vs PCOSpost-metformin: 3.24±0.71 vs 8.17±1.26%, P = 0.003). ET-1 levels were significantly higher in the PCOS women compared with the control group (7.23±0.50 vs 4.99±0.69 fmol/l, P = 0.01), they improved significantly after metformin treatment (PCOSpre-metformin vs PCOSpost-metformin: 7.23±0.50 vs 3.57±0.60 fmol/l, P < 0.0001) and their difference compared with the control group was reversed (PCOSpost-metformin vs controls: 3.57±0.60 vs 4.99±0.69 fmol/l, P = 0.13). Metformin administration improved hyperandrogenemia. However, in this study, mathematical methods used to assess insulin resistance failed to show any detected alteration after treatment with metformin.
Conclusions: PCOS women were found to exhibit endothelial dysfunction compared with controls, which was reversed 6 months after metformin administration.
This article has been cited by other articles:
![]() |
D. Romualdi, B. Costantini, L. Selvaggi, M. Giuliani, F. Cristello, F. Macri, A. Bompiani, A. Lanzone, and M. Guido Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective Hum. Reprod., September 1, 2008; 23(9): 2127 - 2133. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Diamanti-Kandarakis, S. Livadas, S. A Kandarakis, A. Margeli, and I. Papassotiriou Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? Eur. J. Endocrinol., April 1, 2008; 158(4): 525 - 531. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Vollmert, S. Hahn, C. Lamina, C. Huth, M. Kolz, A. Schopfer-Wendels, K. Mann, F. Bongardt, J. C. Mueller, F. Kronenberg, et al. Calpain-10 variants and haplotypes are associated with polycystic ovary syndrome in Caucasians Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E836 - E844. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Diamanti-Kandarakis, T. Paterakis, K. Alexandraki, C. Piperi, A. Aessopos, I. Katsikis, N. Katsilambros, G. Kreatsas, and D. Panidis Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin Hum. Reprod., June 1, 2006; 21(6): 1426 - 1431. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |